Chikara Murakata

3.1k total citations · 1 hit paper
43 papers, 2.7k citations indexed

About

Chikara Murakata is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Chikara Murakata has authored 43 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 11 papers in Organic Chemistry and 9 papers in Pharmacology. Recurrent topics in Chikara Murakata's work include Cancer therapeutics and mechanisms (9 papers), Bioactive Compounds and Antitumor Agents (5 papers) and Trypanosoma species research and implications (5 papers). Chikara Murakata is often cited by papers focused on Cancer therapeutics and mechanisms (9 papers), Bioactive Compounds and Antitumor Agents (5 papers) and Trypanosoma species research and implications (5 papers). Chikara Murakata collaborates with scholars based in Japan, United States and Czechia. Chikara Murakata's co-authors include Masami Kaneko, Yuzuru Matsuda, Kazuyuki Iwahashi, Koji Yamada, Hiroshi Kase, Mitsuru Takahashi, Akira Sato, Satoshi Nakanishi, Tomoya Ogawa and Anna Marie Camoratto and has published in prestigious journals such as Journal of Neuroscience, Blood and Biochemistry.

In The Last Decade

Chikara Murakata

43 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases

1987 873 citations Chikara Murakata, Masami Kaneko et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chikara Murakata Japan	25	1.7k	478	454	349	255	43	2.7k
B. V. L. POTTER United Kingdom	35	2.4k 1.4×	664 1.4×	358 0.8×	291 0.8×	403 1.6×	97	3.6k
Xin-Yun Huang United States	24	2.2k 1.3×	335 0.7×	499 1.1×	480 1.4×	553 2.2×	27	3.4k
Enno Klußmann Germany	40	3.5k 2.1×	172 0.4×	386 0.9×	247 0.7×	383 1.5×	92	4.1k
Danilo Guerini Switzerland	37	3.9k 2.3×	247 0.5×	905 2.0×	308 0.9×	674 2.6×	78	4.8k
Suzie Chen United States	34	2.0k 1.2×	159 0.3×	625 1.4×	675 1.9×	223 0.9×	100	3.1k
Akira Omori Japan	33	2.5k 1.5×	123 0.3×	581 1.3×	256 0.7×	753 3.0×	88	3.5k
Abby L. Parrill United States	34	3.1k 1.8×	371 0.8×	390 0.9×	171 0.5×	676 2.7×	110	3.7k
Tomohiro Tanaka Japan	23	1.0k 0.6×	260 0.5×	165 0.4×	390 1.1×	248 1.0×	152	2.2k
Francisco Cruzalegui France	25	2.0k 1.2×	166 0.3×	415 0.9×	472 1.4×	399 1.6×	51	2.9k
Steven I. Dworetzky United States	31	2.1k 1.3×	507 1.1×	775 1.7×	103 0.3×	115 0.5×	56	3.1k

Countries citing papers authored by Chikara Murakata

Since Specialization

Citations

This map shows the geographic impact of Chikara Murakata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chikara Murakata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chikara Murakata more than expected).

Fields of papers citing papers by Chikara Murakata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chikara Murakata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chikara Murakata. The network helps show where Chikara Murakata may publish in the future.

Co-authorship network of co-authors of Chikara Murakata

This figure shows the co-authorship network connecting the top 25 collaborators of Chikara Murakata. A scholar is included among the top collaborators of Chikara Murakata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chikara Murakata. Chikara Murakata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ye, Xiang S., Fan Li, Robert D. Van Horn, et al.. (2015). A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models. Molecular Cancer Therapeutics. 14(11). 2463–2472. 29 indexed citations

Nakai, Ryuichiro, Shin-ichi Iida, Takeshi Takahashi, et al.. (2009). K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells. Cancer Research. 69(9). 3901–3909. 83 indexed citations

Ishida, Hiroyuki, Taisuke Nakata, Masayo Suzuki, et al.. (2007). A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models. Breast Cancer Research and Treatment. 106(2). 215–227. 29 indexed citations

Shimamura, Michio, Yiying Huang, Naoki Okamoto, et al.. (2007). Glycolipids with nonreducing end α‐mannosyl residues that have the potential to activate invariant Vα19 NKT cells. FEBS Journal. 274(11). 2921–2932. 12 indexed citations

Nakata, Taisuke, Shigemitsu Takashima, Yukimasa Shiotsu, et al.. (2003). Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology. 86(3-5). 455–460. 51 indexed citations

Amishiro, Nobuyoshi, Harumi Ogawa, Tadakazu Akiyama, et al.. (2003). Synthesis and Antitumor Activity of Novel O-Carbamoylmethyloxime Derivatives of Radicicol. Journal of Medicinal Chemistry. 46(12). 2534–2541. 38 indexed citations

Murakata, Chikara, Masami Kaneko, George Gessner, et al.. (2002). Mixed lineage kinase activity of indolocarbazole analogues. Bioorganic & Medicinal Chemistry Letters. 12(2). 147–150. 83 indexed citations

Shiotsu, Yukimasa, Fumihiko Kanai, Chikara Murakata, et al.. (2000). Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia. Blood. 95(12). 3771–3780. 1 indexed citations

Hudkins, Robert L., Mohamed Iqbal, J. Goldstein, et al.. (1998). Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorganic & Medicinal Chemistry Letters. 8(14). 1873–1876. 13 indexed citations

10.

Saporito, Michael S., Susan Carswell, Amy DiCamillo, et al.. (1998). Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis. Neuroscience. 86(2). 461–471. 34 indexed citations

11.

Glicksman, Marcie A., Arlene Y. Chiu, Craig A. Dionne, et al.. (1998). CEP‐1347/KT7515 prevents motor neuronal programmed cell death and injury‐induced dedifferentiation in vivo. Journal of Neurobiology. 35(4). 361–370. 3 indexed citations

12.

Camoratto, Anna Marie, Jitesh P. Jani, Thelma S. Angeles, et al.. (1997). CEP-751 inhibits trk receptor tyrosine kinase activityin vitro and exhibits anti-tumor activity. International Journal of Cancer. 72(4). 673–679. 67 indexed citations

13.

Sasaki, Toru, et al.. (1996). Synthesis of [7ß-methoxy 11C]methoxy staurosporine for imaging protein kinase C localization in the brain. Applied Radiation and Isotopes. 47(1). 67–69. 4 indexed citations

14.

Galski, Hanan, et al.. (1995). Kt-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells. European Journal of Cancer. 31(3). 380–388. 10 indexed citations

15.

Akinaga, Shiro, Tadashi Ashizawa, Katsushige Gomi, et al.. (1992). Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a and its mechanism of action. Cancer Chemotherapy and Pharmacology. 29(4). 266–272. 23 indexed citations

16.

Murakata, Chikara & Tomoya Ogawa. (1992). Stereoselective total synthesis of the glycosyl phosphatidylinositol (GPI) anchor of Trypanosoma brucei. Carbohydrate Research. 235. 95–114. 97 indexed citations

17.

Yamashita, Yoshinori, Noboru Fujii, Chikara Murakata, et al.. (1992). Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 31(48). 12069–12075. 127 indexed citations

18.

Murakata, Chikara, et al.. (1992). Stereoselective synthesis of glycobiosyl phosphatidylinositol, a part structure of the glycosyl-phosphatidylinositol (GPI) anchor of Trypanosoma brucei. Carbohydrate Research. 234. 75–91. 45 indexed citations

19.

TAKAHASHI, ISAMI, Eiji Kobayashi, Hiroyuki Nakano, et al.. (1990). Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C.. Journal of Pharmacology and Experimental Therapeutics. 255(3). 1218–1221. 41 indexed citations

20.

Takano, Seiichi, Chikara Murakata, & Kunio Ogasawara. (1980). A Novel Route to a 16-Subatituted Nine-members Indole Alkaloid Related to Quebrachamine and Cleavamine. Heterocycles. 14(9). 1301–1301. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact